Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2014
Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients.
СтатьяПоддержка правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Plotkin Scott R, Merker Vanessa L, Muzikansky Alona, Barker Fred G, Slattery William
Аннотация
OBJECTIVE: To determine the rate of growth in vestibular schwannomas and the rate of hearing decline in neurofibromatosis type 2 (NF2) patients not undergoing active treatment
STUDY DESIGN: Prospective study.
SETTING: Data were collected at 10 NF2 centers, including hospital-based, academic, and tertiary care centers.
PATIENTS: 120 NF2 patients with 200 vestibular schwannomas.
OUTCOME MEASURES: Hearing decline, defined as a decrease in word recognition score outside the 95% critical difference compared with baseline, and radiographic progression, defined as a 20% or greater increase in tumor volume compared with baseline.
RESULTS: During a total of 313.4 patient-years of follow-up, the rate of hearing decline was 5% at 1 year, 13% at 2 years, and 16% at 3 years; the rate of tumor progression was 31% at 1 year, 64% at 2 years, and 79% at 3 years. For this cohort, the median time to tumor progression (14 mo) was significantly shorter than the median time to hearing decline (62.0 mo).
CONCLUSION: These data provide potentially useful information for the design of clinical trials for NF2 vestibular schwannoma.
STUDY DESIGN: Prospective study.
SETTING: Data were collected at 10 NF2 centers, including hospital-based, academic, and tertiary care centers.
PATIENTS: 120 NF2 patients with 200 vestibular schwannomas.
OUTCOME MEASURES: Hearing decline, defined as a decrease in word recognition score outside the 95% critical difference compared with baseline, and radiographic progression, defined as a 20% or greater increase in tumor volume compared with baseline.
RESULTS: During a total of 313.4 patient-years of follow-up, the rate of hearing decline was 5% at 1 year, 13% at 2 years, and 16% at 3 years; the rate of tumor progression was 31% at 1 year, 64% at 2 years, and 79% at 3 years. For this cohort, the median time to tumor progression (14 mo) was significantly shorter than the median time to hearing decline (62.0 mo).
CONCLUSION: These data provide potentially useful information for the design of clinical trials for NF2 vestibular schwannoma.